Frances Sanofi SA said it would appeal a rejection by US regulators of its new multiplesclerosis drug Lemtrada The Food and Drug Administration expressed concern over serious side effects of the drug and the design of Sanofis clinical trials Lemtrada was approved for sale in Europe Canada and Australia earlier this year The US decision
  